Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,474 across all filing types
Latest filing 2018-09-20 Report Publication Anno…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Notification Letter with Request Form to Non-Registered Holders of Shares - Notice of Publication of Interim Report 2018
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to non-registered shareholders informing them that the company's 2018 Interim Report is available on the company's and HKExnews websites. It provides instructions on how to request a printed version of the report and includes a request form for shareholders to fill out. The document does not contain the actual interim report or substantive financial data but rather serves as a notification and communication about the availability of the report. The document length is 6354 characters, which is relatively short and consistent with a notification letter rather than a full report. Therefore, according to the 'Menu vs Meal' rule, this document is an announcement regarding the publication of a report, not the report itself. Hence, the appropriate classification is Report Publication Announcement (RPA).
2018-09-20 English
Interim Report 2018
Interim / Quarterly Report Classification · 100% confidence The document contains detailed financial statements and analysis for a six-month period ending June 30, 2018, including interim condensed consolidated statements of profit or loss, comprehensive income, financial position, changes in equity, and cash flows. It also includes management discussion and analysis, corporate information, and a review report of interim financial information. The presence of interim financial statements and substantive financial data for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2018
2018-09-20 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2018
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/08/2018. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. It is addressed to the Hong Kong Exchanges and Clearing Limited and includes detailed tables of share capital changes and related information. The content focuses on share capital changes and movements rather than financial performance, earnings, or management commentary. This type of document is a regulatory filing reporting share capital movements, which fits the category of Share Issue/Capital Change (SHA). The document length is substantial and contains detailed data, not just an announcement or a certification, so it is not RPA or RNS. Therefore, the appropriate classification is SHA with high confidence.
2018-09-06 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 August 2018
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/8/2018. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share capital changes. The content is focused on share capital changes and movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements to the Hong Kong Exchanges and Clearing Limited. The document is not an announcement of a report but a detailed monthly return. This fits the category of Share Issue/Capital Change (SHA) as it reports on share capital movements, new shares issued, share options exercised, and other capital changes.
2018-09-04 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2018
Interim / Quarterly Report Classification · 95% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2018' and contains detailed financial highlights, business review, product pipeline updates, and management discussion and analysis for the six-month period ending June 30, 2018. It includes unaudited condensed consolidated interim results and substantive financial data and analysis. The length of the document is about 15,000 characters, indicating it is a full report rather than a brief announcement. The content matches the characteristics of an Interim / Quarterly Report, which covers a period shorter than a full fiscal year and includes actual financial statements and analysis. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). H1 2018
2018-08-31 English
CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG
Regulatory Filings Classification · 95% confidence The document is a short announcement from Ascletis Pharma Inc. regarding a change in the company's principal place of business in Hong Kong. It is signed by the Chairman and includes details about the board composition. There is no financial data, no mention of a report or meeting, and the content is purely an operational update about the company's office location. The document length is only 1357 characters, which is quite short and does not contain any financial statements or detailed management discussion. This fits the category of a general regulatory announcement about company information changes, which falls under Regulatory Filings (RNS).
2018-08-31 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.